Novel use of N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2- phenylethene sulfonamide or its pharmaceutically acceptable salt, i.e., amelioration in the following specific syndromes of patients with diabetes: (1) an increase in blood glucose level; (2) an increase in blood lipid level following the occurrence of early nephropathy; (3) renal functional disorder following the occurrence of early nephropathy; (4) an increase in urinary albumin discharge following the occurrence of early nephropathy; (5) glomerular overfiltration following the occurrence of early nephropathy; (6) renal functional disorder following the transition into chronic renal insufficiency; and (7) an increase in urinary protein discharge following the transition into chronic renal insufficiency.
